Esfahani, Khashayar

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 526

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 351

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 224

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 200

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersRenal Transplantation Outcomes and Treatments

Cited by 109

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 65